ATORVASTATIN 10mg. IP + CLOPIDOGREL 75mg. IP

A combination of statin and antiplatelet for the treatment of patients with various cardiovascular disorders such as heart attacks and strokes. A safe and effective 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor that lowers low-density lipoprotein (LDL) and total cholesterol levels. (Wierzbicki, 2001) Blocks platelets from sticking together by inhibiting the adenosine diphosphate receptor and prevents them from forming harmful clots. (Manuel Rodríguez-Yáñez, 2011) An effective anti-platelet agent used to treat and prevent a variety of thrombotic diseases. (Dawn S. Kuszynski, 2022) More effective than that of Atorvastatin (10 mg) and acetylsalicylic acid (300 mg) in inhibiting ADP-mediated platelet aggregation and expression of major platelet receptors after coronary artery bypass grafting. (Sermin Tetik K. A.-D., 2010) Provides greater platelet inhibition than acetylsalicylic acid and atorvastatin therapy after coronary artery bypass grafting. (Sermin Tetik, 2010) Shows an improved platelet inhibition compared to clopidogrel given alone in patients with ischemic heart disease. (Sermin Tetik, 2010) Produces greater low-density lipoprotein and triglyceride reductions than other statins due to its long-lasting action. (Roxana Sadeghi, 2014)